Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 20Active not recruiting 4Withdrawn 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × veliparib × Clear all
NCT03044795 2024-05-03

REPAIR

University Medical Center Groningen

Phase 2 Withdrawn
Tumor-Agnostic

Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

The University of Texas Health Science Center at San Antonio

Phase 2 Withdrawn
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡